Trials / Active Not Recruiting
Active Not RecruitingNCT06376045
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 317 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rocatinlimab | Rocatinlimab will be administered by SC injection. |
| DRUG | Placebo | Placebo will be administered by SC injection. |
Timeline
- Start date
- 2024-05-24
- Primary completion
- 2026-10-19
- Completion
- 2026-12-11
- First posted
- 2024-04-19
- Last updated
- 2025-12-11
Locations
154 sites across 19 countries: United States, Argentina, Australia, Bulgaria, Canada, Chile, China, Colombia, Czechia, Hong Kong, Hungary, Japan, Mexico, Poland, Romania, South Korea, Taiwan, Thailand, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06376045. Inclusion in this directory is not an endorsement.